The concept of functional neutrophil subsets is new and their clinical significance in malignancies is unknown. dim neutrophil subset, providing evidence for its increased migration capacity, its anti-tumor activity including increased NET formation and finally its correlation with increased survival in HNSCC patients.
Introduction
Neutrophils are innate immune cells that play an essential role in the defense against pathogens and are key effector cells in inflammation and inflammatory diseases. They are the first leukocytes to be recruited to the site of inflammation, which is a crucial event for the clearance of infection. Neutrophils are short-lived cells, but their lifespan is prolonged upon activation. [1] [2] [3] Neutrophil extracellular traps (NETs) have defined new roles for neutrophils in inflammation and immunity, and are important for the neutrophil-mediated antimicrobial defense. NETs are extracellular neutrophil-derived structures composed of DNA, decorated with antimicrobial peptides such as neutrophil elastase (NE). 4, 5 In addition to pathogen defense, neutrophils have also been shown to influence B-cell function and to inhibit T-cell activation and proliferation. 6, 7 Pillay et al. recently divided neutrophils into three different subsets in the circulation of patients with an acute systemic inflammation, based on the expression of CD16 and CD62L. The CD16 dim CD62L high subset showed characteristics of neutrophils derived from the bone marrow, CD16 high CD62L high cells were phenotypically normal mature neutrophils, and CD16 high CD62L dim neutrophils displayed a hypersegmented nucleus. 6 There is emerging evidence for distinct neutrophil subsets with diverse roles in inflammation and cancer immunology, 6, 8 but a clinical link remains to be established. In particular, the role of neutrophils in cancer-related inflammation has received increased attention, with some studies suggesting a tumor-promoting role for neutrophils, 9, 10 and other studies pointing toward anti-tumoral activity. [11] [12] [13] In head and neck squamous cell carcinoma (HNSCC) patients are known to display altered neutrophil activation compared to healthy controls. [14] [15] [16] The aim of our study was to characterize different neutrophil subsets by their expression of CD16 and CD62L, and to determine their role in HNSCC. These findings demonstrate an anti-tumoral role of the CD16 high CD62L dim neutrophil subset in HNSCC and indicate the complexity of neutrophil involvement in cancer regulation.
Material and Methods

Patients
Samples from a total of 46 HNSCC patients were used for our study. Blood was obtained from 20 patients (14 males and six females) with HNSCC before initiation of treatment, along with 19 (eight males and 11 females) age-and sexmatched healthy controls. The median age of the patients was 65.5 years (range 52-87) and the median age of the controls was 66 years (range 51-89). Also, granulocytes were isolated from blood obtained from 12 newly diagnosed, untreated HNSCC patients (eight males and four females) with a median age of 65 (range 54-85). Tumor biopsies along with a blood sample from 22 HNSCC patients were collected at the time of the diagnostic endoscopy. Twelve biopsies were embedded in paraffin, sliced in 3 mm sections, and mounted on glass slides, and ten biopsies were used for flow cytometry analysis. Blood was also collected from 12 healthy donors to determine the impact of activated neutrophils on the anti-tumor immune response. The patient groups and their relationship with the study experiments are represented in Supplementary Figure S1 . Individuals with autoimmune disorders, on-going immune-modulating medication and previous malignant diseases were excluded. The clinical tumor (T) and lymph node (N) classification of the cancer patients at the time of inclusion are shown in Supplementary Table S1 . The different tumor locations in the patient were as follows: five nasopharyngeal, three esophageal, 11 tonsillar, one gingival, four laryngeal, six hypopharyngeal, five at the base of the tongue, three oral tongue, five supraglottic, one oropharyngeal and finally one at the floor of the mouth. For one of the patients, the primary tumor could not be located, i.e. cancer of unknown primary (CUP). Our study was approved by the regional ethics committees at Karolinska Institutet and Lund University, and a written consent was obtained from all participants.
Antibodies
The following antibodies (Abs) were purchased from Beckman Coulter (Marseille, France): CD11b-FITC (BEAR1), CD16-PC5 (3G8), CD16-ECD (3G8), CD45-PE (J.33) and CD62L-PE (DREG56). CD11b-APC (ICRF44), CD16-FITC (3G8), CD16-V450 (3G8), CD45-APC-Cy7 (2D1), CD181-APC (CXCR1; 5A12) and CD182-FITC (CXCR2; 6C6) were from BD Bioscience (San Jose, CA), whereas CD18-FITC (212701) was obtained from R&D systems (Minneapolis, MN). All antibodies used were monoclonal (mAbs).
Cell separation
Peripheral blood was collected in heparin tubes, diluted 1:1 with phosphate buffered saline (PBS) solution and centrifuged using Ficoll-Paque (Amersham Bioscience, Uppsala, Sweden). The granulocyte-rich pellet was recovered and treated with ammonium chloride erythrocyte lysis solution (0.155 mM NH 4 Cl, 10 mM KHCO 3 and 0.1 mM EDTA) for 15 min on ice. The cell suspension was centrifuged, washed in PBS, and resuspended to a density of 4 3 10 6 cells/mL in complete medium, consisting of RPMI-1640 supplemented with 0.3 g/L L-glutamine (Sigma Aldrich, St. Louis, MO), 100 U/mL penicillin and 100 mg/mL streptomycin (Gibco, Invitrogen, Carlsbad, CA), and 10% autologous plasma.
Flow cytometry analysis
Flow cytometry analyses were performed on a Coulter Epics XL, a Beckman Coulter Navios or a BD LSRFortessa flow cytometer. Events in the range 40,000-100,000 were collected, and analyzed with either CXP analysis software (Applied Cytometry Systems, Dinnington, UK) or FlowJo software (Tree Star, Inc., Ashland, OR). To ensure flow cytometric standardization, the voltage settings were updated daily using FlowSet calibration beads. All Abs were titrated before use. For extracellular whole blood staining, 50 mL of blood were incubated with mAbs for 20 min. Erythrocytes were lysed with 600 mL of 0.1% (v/v) formic acid for 3-5 sec and the ionic strength was rendered iso-osmotic by addition of 280 mL of 51 mM Na 2 CO 3 , 0.20 M Na 2 SO 4 and 0.22 M NaCl for neutrophil subset characterization. However, for phenotype description of the different neutrophil subsets, erythrocytes were lysed with ammonium chloride erythrocyte lysis solution. Tumor biopsies were homogenized, treated with FBS to decrease the unspecific Ab binding, and incubated with mAbs for 20 min.
Immunohistochemistry
Tumor sections (3 mm) were deparaffinized in xylene, rehydrated in ethanol, and incubated with target-retrieval solution for 20 min in a microwave oven. The sections were treated with 1% Triton-X-100 followed by hydrogen peroxidase. Primary mouse mAbs against CD16 (diluted 1:50), NE (1:200) and IL-8 (1:1,000) were applied to the sections for 2 hr. Nseries Universal Negative Control Mouse (DakoCytomation, Copenhagen, Denmark) was used as the control. For detection, the sections were incubated with horseradish peroxidase (HRP)-labeled goat anti-mouse polymer for 30 min, followed by 3,3-diaminobenzidine (DAB) substrate-chromogen for 10 min. The nuclei were visualized by haematoxylin staining. Subsequently, the sections were dehydrated with ethanol, washed with xylene, and mounted. An Olympus Provis AX70 microscope (Olympus, Hamburg, Germany) with a Pixera pro 150ES camera (Pixera, San Jose, CA), and the software Pixera Viewfinder 3.0.1 was used to view and photograph the slides.
Chemotaxis assay
Cell culture inserts with 5 mm pores (Corning, NY) were placed in 24-well culture plates containing complete medium supplemented with or without 10 ng/mL of the chemoattractant interleukin (IL)28 (R&D systems). As a control, non-migrating cells treated with or without 10 ng/mL IL-8 were used. The IL-8 concentration was determined by a concentration-response experiment investigating the percentage of migrating cells in response to different IL-8 concentrations. The isolated granulocytes were added to the upper surface of the filters and allowed to migrate for 1 hr in 378C in a humidified 5% CO 2 air atmosphere. Afterwards, the migrating neutrophils were incubated with mAbs for 20 min and analyzed on a Beckman Coulter Navios flow cytometer.
Granulocyte activation
Granulocytes were cultured in complete medium at a density of 4 3 10 6 cells/mL with or without 10 ng/mL IL-8 (R&D systems) for 60 min or 120 min. The IL-8 concentration used was determined by concentration-response experiments. When granulocytes were activated for migration, XTT and growth co-culture assays 200 mL cell suspension per well was plated on 96-well plates, whereas for co-culture apoptotic assay 1 mL granulocyte was activated in 24-well plates. After activation the cells were harvested, washed and cultured with or without the HNSCC cell line FaDu or incubated with mAbs for 20 min and subsequently analyzed on a Beckman Coulter Navios flow cytometer.
HNSCC cell line and isolation of primary human nasal epithelial cells (HNEC)
The human pharyngeal squamous cell carcinoma cell line FaDu (HTB-43; ATCC, Manassa, VA) was cultured in minimal essential medium (MEM) with Earl's salts and 2 mM L-glutamine (Gibco), and supplemented with 10% fetal bovine serum (FBS; PAN Biotech, Aidenbach, Germany), 100 U/mL penicillin and 100 mg/mL streptomycin (Gibco). HNEC were isolated from 6 healthy non-smoking individuals as previously described. 17, 18 Cells were cultured in airway epithelial cell growth medium supplemented with 0.4% bovine pituitary extract, 10 ng/mL epidermal growth factor, 5 mg/mL insulin, 0.5 mg/mL hydrocortisone, 0.5 mg/mL epinephrine, 6.7 ng/mL triiodothyronine, 10 mg/mL transferrin, 0.1 ng/mL retinoic acid (PromoCell, Heidelberg, Germany), 100 U/mL penicillin and 100 mg/mL streptomycin (GIBCO). Primary cells in passage 1-3 were used in the experiments and they were all positive for epithelial cell adhesion molecule (EpCAM) (>90%), an adhesion molecule specific for epithelial cells. The cells were cultured in tissue culture flasks at 378C in humidified 5% CO 2 air atmosphere.
ELISA
The levels of IL-8 (sensitivity level 3.5 pg/mL) in cell culture supernatants were analyzed with ELISA plates from R&D systems.
Migration assay
To examine the impact of activated neutrophils on the migration of FaDu cells, the Oris Cell Migration Assay Kit from AMS Biotechnology (Abingdon, UK) was used. Briefly, FaDu cells were plated (1 3 10 5 cells/well) on a 96-well migration plate in 100 mL of complete medium for 24 hr to allow cell attachment. The inserts were removed (except for the reference wells), the cells were washed, and IL-8-activated neutrophils (400,000 cells) or complete medium alone was added. The neutrophils were activated with 10 ng/mL IL-8 on a 96-well plate for 2 hr and washed before addition to the FaDu cells on the migration plate. After another 24 hr of incubation, to allow the tumor cells to migrate, the cells were fixed, treated with Giemsa staining and their migration was analyzed by microscopy. An Olympus Provis AX70 microscope with a Pixera pro 150ES camera, and the software Pixera Viewfinder 3.0.1 was used to view and photograph the wells. The percentage of the migrated cell area was determined using ImageJ software (NIH, Washington, DC) and calculated as migrated area 5 total area -non-migrated area.
Apoptosis
The Vybrant Apoptosis Assay Kit #3 from Molecular Probes was used to assess the impact of activated neutrophils on the percentage of viable, apoptotic and dead tumor cells. FaDu (250,000 cells/well) was plated on a 24-well plate and incubated for 24 hr to allow cell attachment. The cells were washed and IL-8-activated neutrophils (2,000,000 cells) or complete medium was added. After 4 or 24 hr of cultivation, the cells were harvested and stained with Annexin-V-(ANXV)-FITC and propidium iodide (PI) as well as CD16-PC5 and CD45-PE.
XTT assay
FaDu (50,000 cells/well) was plated in a 96-well plate in 200 mL complete medium for 24 hr to allow cell attachment. Subsequently, IL-8-activated neutrophils (400,000 cells) or complete medium was added. The cells were cultured for an additional Tumor Immunology and Microenvironment 21 hr, thereafter 50 mL XTT labeling mixture was added and the cells incubated for 3 hr. The optical density was measured at 450 nm in a microplate reader.
Growth
FaDu cells (50,000 cells) were plated on a 96-well plate and incubated for 24 hr to allow attachment. IL-8-activated neutrophils (400,000 cells) or complete medium was added and the cells were cultured for an additional 3 days. Thereafter, the cells were washed, fixed and treated with Giemsa staining.
NETs assay
After neutrophils were activated with 10 ng/mL IL-8 for 2 hr the production of NETs was assessed using the NET assay kit from Cayman Chemicals (Ann Arbor, MI) according to the manufacturer's instructions.
Statistics
Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, San Diego, CA), and data are presented as mean 6 standard error of the mean (SEM). n is equal to the number of independent donors, and p-values of 0.05 were considered statistically significant. For normally distributed unpaired data, the unpaired student's t-test, with Welch correction if the variance was non-homogenous, was used. One-way repeated measures analysis of variance (ANOVA) with Tukey's post-hoc test was used for comparison of more than two sets of paired data that were normally distributed; when two sets of paired data were compared the Student's t-test was utilized. The survival function from survival data was estimated using Kaplan-Meier analysis, and a log-rank test was utilized to examine the significance of the different survival distributions between the two groups.
Results
Neutrophil subsets in patients with HNSCC
Flow cytometry was used to define neutrophil subsets in blood obtained from HNSCC patients. Three subsets were found: CD16 dim CD62L high , CD16 high CD62L high and CD16 high CD62L dim (Fig. 1a) . There was no difference in the fraction of CD16 dim CD62L high (Fig. 1b, left Fig. 1b, right panel) .
CD16
high CD62L dim neutrophils display a distinct phenotype
The phenotypical differences between the neutrophil subsets were then further characterized using flow cytometry. (Fig. 1c) . Thus, the subpopulation CD16 high CD62L dim neutrophils from HNSCC patients is distinct with an elevated expression level of CD11b and CD18, suggesting an increased capacity to bind complement C3b and C4b and migrate during an inflammatory response.
high CD62L dim neutrophils are prone to migrate
Immunohistochemical staining revealed a large amount of CD16-positive cells in HNSCC tumors. They were mainly seen in the stroma, but some positive cells could also be detected in close contact with tumor cells (Fig. 2a) . (Fig. 2b) .
A migration assay with purified blood granulocytes was used to investigate which of the three neutrophil subsets found in blood was most prone to migrate into the tumor. The CD16
high CD62L dim population appeared to have the highest migration ability, whereas the CD16 dim CD62L
high neutrophils migrated least (data not shown). The same pattern was seen for IL-8-facilitated migration (Fig. 2c) . However, the expression of the IL-8 receptors CXCR1 and CXCR2 did not differ between the three subsets (data not shown). During the IL-8-induced migration, an increase in the CD16 high CD62L dim cells was observed at the expense of the other two subsets, suggesting that IL-8 induces maturation of neutrophils. Indeed, when culturing isolated granulocytes for 1 hr in the presence of IL-8, the fraction of CD16 high CD62L dim neutrophils increased significantly and the fraction of CD16 dim CD62L high cells decreased (Fig. 3a) . In addition, the percentage of CD16 high CD62L high neutrophils was also somewhat reduced (Fig. 3a) . With immunohistochemical staining, IL-8 was detected within HNSCC tumors (Fig. 3b) . Cultivation of the HNSCC cell line FaDu and primary HNEC confirmed that tumor cells secrete IL-8 and revealed a higher release of IL-8 from FaDu cells compared to HNEC (Fig. 3b) . This suggests that HNSCC cells express IL-8, which promotes differentiation of neutrophils into the CD16 high CD62L dim subpopulation, the subpopulation with the best IL-8 migratory response.
Activated neutrophils exhibit an anti-tumor immune response
The impact of the activated neutrophils, CD16 high CD62L dim , on HNSCC cells was determined using migration, apoptosis, proliferation and tumor cell growth assays. Neutrophils were activated with IL-8 to establish the neutrophil profile seen among the HNSCC patients. However, when non-activated neutrophils were added to the tumor cells, the neutrophils attained an activated profile similar to the IL-8-stimulated cells. This was expected, since tumor cells secret high levels of IL-8 (Fig. 3b) . Consequently, a control using non-activated cells was not possible in these experiments. Nonetheless, IL-8-activated neutrophils were found to inhibit the migration of the tumor cell line FaDu (p 5 0.0054; Fig. 4a) . A decrease in the fraction of living tumor cells and an enhancement of the amount of apoptotic cells was detected after 24 hr of cultivation 
Tumor Immunology and Microenvironment
with activated neutrophils (Viable p 5 0.0171; Apoptotic p 5 0.0174; Fig. 4b ). This was detected already after 4 hr (data not shown). The amount of dead cells represented <0.5% of the total amount of tumor cells and could therefore be disregarded. Analogously, a decreased proliferation of FaDu was also detected after incubation with IL-8-activated neutrophils for 24 hr (p 5 <0.0001; Fig. 4c ). When the tumor cells were allowed to grow to confluence, activated neutrophils also prevented the growth of HNSCC cells (Fig. 4d) . Thus, IL-8-activated neutrophils inhibit tumor cell migration, induce tumor cell apoptosis and inhibit tumor cell proliferation.
NETs are involved in the anti-tumor immune function of activated neutrophils
To understand the anti-tumoral mechanism behind IL-8-activated neutrophils, IL-8-activated and non-activated neutrophils were investigated with regard to NET formation. Activated neutrophils were found to produce more NETs than untreated neutrophils (Fig. 5a) . The presence of NETs within tumor tissue was determined with immunohistochemical staining of NE. NE is a major component in NETs 4, 5 and was detected within the tumor, both in the stroma and among the tumor cells (Fig. 5b) . The release of NETs was found to take place inside the tissue and not in the circulation, and tumor cells were not found to produce any NETs (data not shown).
CD16
high CD62L dim neutrophils predict patient survival
Further scrutiny of the proportion of CD16 high CD62L dim neutrophils in blood from HNSCC patients revealed the existence of two patient groups, one with a high and one with a low fraction of CD16 high CD62L dim neutrophils, the latter corresponding to numbers seen in healthy controls (Fig. 1b) . Cancer patients with a high proportion of circulating CD16 high CD62L dim neutrophils had a significantly improved survival time compared to patients with a low fraction of CD16 high CD62L dim neutrophils (p 5 0.015; Fig. 6 ). The T and N classification, stage and tumor localization appeared to be evenly distributed between the two groups (Supplementary Table S2 ).
Discussion
Three neutrophil subsets with distinct phenotypes were identified in peripheral blood from patients with HNSCC. The subgroup characterized as CD16 high CD62L dim cells was more prevalent among the cancer patients than among controls. The CD16 high CD62L dim cells displayed an activated phenotype, were more prone to migrate compared to the other subsets, had anti-tumor immune functions (inhibition of migration, proliferation of cancer cells and induced cancer cell apoptosis) and increased presence of NETs. Despite a small patient material, an increase in CD16 high CD62L dim neutrophils in the circulation was linked to increased survival among HNSCC patients. The three neutrophil subsets identified by Pillay et al. 6 were found in the circulation of patients with HNSCC. The CD16 high CD62L dim neutrophils demonstrated the most activated phenotype of the three subsets, and this subset was elevated among the cancer patients compared to healthy controls. In addition to the CD16 high CD62L dim cells, additional subsets were found in the tumor: CD16 dim CD62L dim , CD16 dim CD62L neg and CD16 high CD62L neg neutrophils. This underscores the notion that the neutrophil subsets are not fixed populations, but rather represent different stages of activation. We hypothesized that the neutrophil subsets represent neutrophils at different stages of activation/maturation and that CD16 high CD62L dim may represent the mature and activated stage of neutrophil development.
The enhanced migratory capacity of the CD16 high CD62L dim subset is in line with its prominent MAC-1 complex expression [19] [20] [21] [22] and low CD62L expression. [22] [23] [24] For a proper homing neutrophils shed their CD62L expression, which occurs through activation, [22] [23] [24] indicating that neutrophils have to get a CD62L-dim phenotype to migrate. Therefore, excluding migration of CD16 high CD62L high cells is not possible since they may have been activated and become CD16 high CD62L dim cells. Tumors secret a wide variety of cytokines and chemokines that will have the ability to further activate and affect the neutrophils. [25] [26] [27] Thus, when the CD62L-dim neutrophils have migrated into the tumor they are transformed into tumor associated neutrophils with a more CD16-and CD62L-dim/negative phenotype. The CD16 high CD62L dim neutrophils might therefore represent a transitional activated stage with an increased migratory capacity.
The CD16 high CD62L dim subset's ability to respond to IL-8 does not seem to be related to its expression of the IL-8 receptors CXCR1 and CXCR2, as the levels were the same for all subsets. Instead, it may be related to downstream signaling that is linked to the maturation process. Tumor cells secrete high levels of IL-8, but other cells within the tumor microenvironment are also known to produce IL-8. 15, 28, 29 Consequently, IL-8-induced dim cells have a reduced binding to activated endothelial cells and an impaired chemotaxis toward end-target chemoattractants. 30 The involvement of endothelial binding in migration demonstrates the complex role of these subsets.
IL-8 was demonstrated to be a maturation factor for neutrophils and to be involved in the development of the different neutrophil subsets. Other cytokines such as interferon-g and granulocyte-macrophage colony-stimulating factor (GM-CSF) have also been demonstrated to enhance the fraction of CD16 high CD62L dim neutrophils. 31 As IL-8, GM-CSF is also known to be produced and secreted by tumor cells, 25, 32, 33 indicating that it is the environment, and in this case the tumor induced environment, rather than a single mediator that gives rise to the elevated levels of CD16 high CD62L dim cells in the circulation. There might also be other tumor secreted mediators except for IL-8 and GM-CSF that can induce CD16 high CD62L dim neutrophils. An increased fraction of CD16 high CD62L dim neutrophils was correlated with improved survival among HNSCC patients. This analysis included a small number of patients and a larger patient sample has to be studied to get a firm conclusions of the prognostic value of CD16 high CD62L dim cells on the patient survival. Still, many questions remain regarding the mechanisms in which CD16 high CD62L dim neutrophils exhibit their anti-tumoral activity. However, in some way NETs seem to contribute to the anti-tumoral function of the CD16 high CD62L dim cells. The role of NETs in the tumor immune response is poorly understood and has yet to be unraveled. The few studies that have been conducted suggest an association between NETs and cancer 
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progression and tumor-associated thrombosis. 5 However, these studies were mostly performed in murine models 5 which are not fully comparable to humans, since murine neutrophils are very different from human neutrophils. 34, 35 NETs were presently found to be produced within the tumors by activated neutrophils. These neutrophils exhibited an ability to inhibit the migration, proliferation and growth of HNSCC cells. This suggests a direct anti-tumor function for these activated neutrophils that can be mediated by NETs.
Human cancer deaths are often due to the formation of metastases and therefore the inhibition of the migration and growth of tumor cells is of importance. 36 In contrast to our results, other studies showed that supernatant from neutrophils, treated with culture medium from cancer cells, increases the migration of HNSCC cells. 37 This indicates that the anti-tumor function of activated neutrophils is most likely mediated by cellto-cell contact. Neutrophils have been attributed with both proand anti-tumor functions. Pillay et al. demonstrated that the CD16 high CD62L dim neutrophil subset has immune suppressive properties and could be a potential target to prevent immune suppression in cancer. 6 This is in agreement with studies reporting that high levels of tumor-infiltrating and blood neutrophils are associated with a poor outcome. 9, 10 However, there is also convincing evidence of an anti-tumorigenic activity of neutrophils [11] [12] [13] . It might be that there are two different forms of neutrophils, one with anti-tumorigenic properties, often referred to as N1, and one with pro-tumorigenic properties, called N2. 8 Thereby, the different neutrophil subpopulations might represent N1 and N2 neutrophils. It has been reported that a neutrophil population, characterized by a hypersegmented nucleus, has anti-tumorigenic properties. These cells were described to be in a heightened state of activation. 8, 38 This agrees well with the CD16 high CD62L dim subset that displays a similar morphology with a hypersegmented nucleus 6 and appears to have antitumorigenic properties. In addition, the MAC-1 complex has been demonstrated to be of importance for the tumor cytolytic function of neutrophils. 12 The ) play in this mechanistic, biological "tug-of-war" is also of interest. There are many questions that require continuing research to define the mechanisms of anti-tumoral neutrophil subset activity, which if revealed, may open up new avenues for innovative means of treatment for HNSCC.
In conclusion, neutrophils are generally considered to be a homogenous population and the clinical relevance of neutrophil subsets are seldom considered because of their short half-life. However, our study links the occurrence of specific neutrophil subsets with increased NET activity and cancer survival. Our study suggests that neutrophils may have a beneficial role in HNSCC. Figure 6 . Presence of CD16 high CD62L dim neutrophils in blood indicates improved survival. The head and neck squamous cell carcinoma (HNSCC) patients were split into two groups, one with a high level of CD16 high CD62L dim neutrophils and another with low levels of CD16 high CD62L dim cells. A Kaplan-Meier analysis depicts the survival of the two groups. *p 0.05.
